Know Labs Acquires Bitcoin Treasury Strategy with Greg Kidd as CEO

Know Labs, Inc. has announced a significant strategic move with the acquisition of a controlling interest by Goldeneye 1995 LLC, an affiliate of fintech investor and entrepreneur Greg Kidd. Kidd, who previously served as the Chief Risk Officer at Ripple, will assume the roles of Chief Executive Officer and Chairman of the Board of Directors upon the transaction's closure. The deal involves the acquisition of a specific number of Know Labs' common stock, determined by dividing the sum of 1,000 Bitcoin and a cash sum to retire existing debt, redeem outstanding preferred equity, and provide additional working capital, by the per share purchase price of $0.335. The Bitcoin will be integrated into the Company’s treasury strategy, offering investors substantial economic exposure to this digital asset.

Kidd expressed enthusiasm about deploying a Bitcoin treasury strategy with Know Labs, citing favorable market and regulatory conditions. He believes this approach will drive sustainable growth and long-term shareholder value. Kidd and his team bring extensive expertise in digital assets and will transition their existing Bitcoin yield generation strategy to the public markets through this deal. The Bitcoin holdings will become the principal component of the Company’s balance sheet, with management using the multiple of net asset value (mNAV) metric to measure the premium or discount investors ascribe to the Company’s market valuation relative to its Bitcoin holdings. Given a market capitalization of $128 million, the implied entry mNAV multiple is 1.22x, with Bitcoin holdings representing 82% of the market capitalization at closing, assuming a price of $105,000 per Bitcoin.

Founder Ron Erickson will serve as President of a new division, retaining a team of scientists to continue the Company’s proprietary diagnostic research. Upon the transaction's closure, Erickson will become Vice Chairman of the Board. Erickson highlighted the partnership with Kidd as a pivotal next chapter for Know Labs, expressing excitement about continuing their research in non-invasive medical technology and positioning the Company for a bold future under Kidd's leadership. The transaction, unanimously approved by the Know Labs Board of Directors, is expected to close in the third quarter of 2025, following shareholder approval and the satisfaction of customary closing conditions.

Greg Kidd is the co-founder and CEO of Hard Yaka, a venture capital firm, and the majority shareholder of OCC-chartered Vast Bank. As an investor, Kidd has provided first money at prominent companies such as Twitter, Square (Block), Coinbase, Robinhood, and Solana. Other early investments include Ripple, Uphold, and Brave. Kidd's career includes working at consulting firm Booz Allen Hamilton, taking his first company public on the NASDAQ in the 1990s, serving in the payments division of the Federal Reserve, and as a director at Promontory Financial Group. He also served as Chief Risk Officer at Ripple and graduated from Brown University, earning an MBA from Yale University and an MPA in public policy from Harvard’s Kennedy School. Kidd was a nonpartisan 2024 candidate for Congress in Nevada's 2nd District.

Know Labs, Inc. is a public company whose common shares trade on the NYSE American Exchange under the stock symbol “KNW.” The Company’s platform technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. This patented and patent-pending technology can be integrated into various wearable, mobile, or bench-top form factors, making it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of the technology will be in a product marketed as a non-invasive glucose monitor, providing users with accessible and affordable real-time information on blood glucose levels. This product will require U.S. Food and Drug Administration clearance prior to its introduction to the market. Other products based on the Company’s technology may not require such FDA approval.